Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men

  • Rosell Díaz, Marisel
  • Petit Gay, Anna
  • Molas Prat, Clàudia
  • Gallardo Nuell, Laura
  • Ramió Torrentà, Lluís
  • Garre Olmo, Josep
  • Pérez Brocal, Vicente
  • Moya, Andrés
  • Jové Font, Mariona
  • Pamplona Gras, Reinald
  • Puig, Josep
  • Ramos, Rafael
  • Bäckhed, Fredrik
  • Mayneris Perxachs, Jordi
  • Fernández Real, José Manuel
Background : An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D. Aim : To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively. Methods : We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (n = 172); (2) people with long-term T2D on metformin monotherapy (n = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (n = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (n = 22). Analyses were also performed stratifying by sex. Results : Several bacterial species belonging to the Proteobacteria (Escherichia coli) and Verrucomicrobia (Akkermansia muciniphila) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (Romboutsia timonensis, Romboutsia ilealis) were negatively associated. Due to the consistent increase in A. muciniphila and decrease in R.ilealis in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the A.muciniphila/R.ilealis ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the A.muciniphila/R. ilealis ratio was significantly and positively associated with higher memory scores and improved memory in men. Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (astA, astB, astC, astD, astE, putA), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate. Conclusions : The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites., This work was partially funded by Instituto de Salud Carlos III (ISCIII, Madrid, Spain) through the projects PI15/01934 and PI21/ 01361 to J.M.F-R and the project PI20/01090 and PI23/00575 (co-funded by the European Union under the European Regional Development Fund (FEDER) “A way to make Europe”) to J.M-P. Generalitat de Catalunya (2021 SGR 01263). M.R.D. is funded by Girona Biomedical Research Institute (Girona, Spain) through the Horizon 2020 Framework Programme of the European Union under the Marie Skłodowska- Curie Innovative Training Network grant agreement No 859890. Open Access funding provided by the CRUE-CSIC agreement with Elsevier. The Aging Imageomics Study has been funded by Pla estrat`egic de recerca i innovaci´o en salut 2016-2020 from Generalitat de Catalunya (reference number, SLT002/16/00250). IRBLleida is a CERCA Programme of the Government of Catalonia. IDIBGI is a CERCA Programme/Generalitat de Catalunya. M.J. is a ‘Serra-Hunter’ Fellow. J.M.- P. is funded by Instituto de Salud Carlos III (Madrid, Spain) through the Miguel Servet Program CP18/00009 (co-funded by European Union under the European Social Fund “Investing in your future”). J.M.-P. was also supported through the project CNS2023-144218 funded by MICIU/ AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men

  • Rosell Díaz, Marisel
  • Petit Gay, Anna
  • Molas Prat, Clàudia
  • Gallardo Nuell, Laura
  • Ramió Torrentà, Lluís
  • Garre Olmo, Josep
  • Pérez Brocal, Vicente
  • Moya, Andrés
  • Jové Font, Mariona
  • Pamplona Gras, Reinald
  • Puig, Josep
  • Ramos, Rafael
  • Bäckhed, Fredrik
  • Mayneris Perxachs, Jordi
  • Fernández Real, José Manuel
Background : An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D. Aim : To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively. Methods : We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (n = 172); (2) people with long-term T2D on metformin monotherapy (n = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (n = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (n = 22). Analyses were also performed stratifying by sex. Results : Several bacterial species belonging to the Proteobacteria (Escherichia coli) and Verrucomicrobia (Akkermansia muciniphila) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (Romboutsia timonensis, Romboutsia ilealis) were negatively associated. Due to the consistent increase in A. muciniphila and decrease in R.ilealis in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the A.muciniphila/R.ilealis ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the A.muciniphila/R. ilealis ratio was significantly and positively associated with higher memory scores and improved memory in men. Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (astA, astB, astC, astD, astE, putA), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate. Conclusions : The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites., This work was partially funded by Instituto de Salud Carlos III (ISCIII, Madrid, Spain) through the projects PI15/01934 and PI21/ 01361 to J.M.F-R and the project PI20/01090 and PI23/00575 (co-funded by the European Union under the European Regional Development Fund (FEDER) “A way to make Europe”) to J.M-P. Generalitat de Catalunya (2021 SGR 01263). M.R.D. is funded by Girona Biomedical Research Institute (Girona, Spain) through the Horizon 2020 Framework Programme of the European Union under the Marie Skłodowska- Curie Innovative Training Network grant agreement No 859890. Open Access funding provided by the CRUE-CSIC agreement with Elsevier. The Aging Imageomics Study has been funded by Pla estrat`egic de recerca i innovaci´o en salut 2016-2020 from Generalitat de Catalunya (reference number, SLT002/16/00250). IRBLleida is a CERCA Programme of the Government of Catalonia. IDIBGI is a CERCA Programme/Generalitat de Catalunya. M.J. is a ‘Serra-Hunter’ Fellow. J.M.- P. is funded by Instituto de Salud Carlos III (Madrid, Spain) through the Miguel Servet Program CP18/00009 (co-funded by European Union under the European Social Fund “Investing in your future”). J.M.-P. was also supported through the project CNS2023-144218 funded by MICIU/ AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Phenol-Enriched Olive Oils on Serum Metabonome and Its Relationship with Cardiometabolic Parameters, A Randomized, Double-Blind, Cross-Over, Controlled Trial

  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Swann, Jonathan Richard
  • Rowland, Ian
  • Rubió, Laura
  • Subirana, Isaac|||0000-0003-1676-0197
  • Catalán, Úrsula
  • Motilva, Maria-José|||0000-0001-8985-7737
  • Solà, Rosa|||0000-0002-8359-235X
  • Covas Planells, Maria Isabel
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Mayneris-Perxachs, Jordi|||0000-0003-3788-3815
Phenol-rich foods consumption such as virgin olive oil (VOO) has been shown to have beneficial effects on cardiovascular diseases. The broader biochemical impact of VOO and phenol-enriched OOs remains, however, unclear. A randomized, double-blind, cross-over, controlled trial was performed with thirty-three hypercholesterolemic individuals who ingested for 3-weeks (25 mL/day): (1) an OO enriched with its own olive oil phenolic compounds (PCs) (500 ppm; FOO); (2) an OO enriched with its own olive oil PCs (250 ppm) plus thyme PCs (250 ppm; FOOT); and (3) a VOO with low phenolic content (80 ppm). Serum lipid and glycemic profiles, serum 1H-NMR spectroscopy-based metabolomics, endothelial function, blood pressure, and cardiovascular risk were measured. We combined OPLS-DA with machine learning modelling to identify metabolites discrimination of the treatment groups. Both phenol-enriched OO interventions decreased the levels of glutamine, creatinine, creatine, dimethylamine, and histidine in comparison to VOO one. In addition, FOOT decreased the plasma levels of glycine and DMSO2 compared to VOO, while FOO decreased the circulating alanine concentrations but increased the plasma levels of acetone and 3-HB compared to VOO. Based on these findings, phenol-enriched OOs were shown to result in a favorable shift in the circulating metabolic phenotype, inducing a reduction in metabolites associated with cardiometabolic diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lower serum ferritin levels are associated with worse cognitive performance in aging

  • Rosell-Díaz, Marisel|||0000-0001-7599-6584
  • Santos-González, Elena
  • Motger Albertí, Anna|||0000-0002-9430-371X
  • Gallardo-Nuell, Laura
  • Arnoriaga-Rodriguez, Maria|||0000-0002-0394-1223
  • Coll-Martínez, Clàudia|||0000-0003-2927-4008
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Garre-Olmo, Josep|||0000-0002-7817-0814
  • Puig, Josep|||0000-0003-2791-6599
  • Ramos, Rafel|||0000-0001-7970-5537
  • Mayneris-Perxachs, Jordi|||0000-0003-3788-3815
  • Fernández-Real Lemos, José Manuel|||0000-0002-7442-9323
Objectives: Iron is important for neurogenesis, synaptic development, and neurotransmitter synthesis. Serum ferritin (SF) is a reliable marker for assessing iron stores. Therefore, we evaluated the cognitive function associated with SF levels. We also assessed brain iron content using R2* Magnetic Resonance Imaging (MRI) and its association with SF levels. Design: Data from three cross-sectional observational studies were used. Aging Imageomics (n = 1030) was conducted on aged subjects. Health Imageomics (n = 971) and IR0NMET (n = 175) were conducted in middle-aged subjects. Setting and participants: Participants were enrolled at Dr. Josep Trueta University Hospital facilities. The three cohorts included a total of 2176 subjects (mean age, 52 years; 48% men). Measurements: SF levels were measured by standard laboratory methods. Total Digits Span (TDS), and Phonemic Verbal Fluency (PVF) were used to assess executive function. Language function was assessed by semantic verbal fluency (SVF), attention by the Symbol Digit Modalities Test, and memory by the Memory Binding Tests - Total Free Recall and Total Delayed Free Recall. MRI was used to assess the iron content of the brain by R2*. Results: In subjects aged 65 years or older, SF levels were associated with increased TDS (β = 0.003, p = 0.02), PVF (β = 0.004, p = 0.01), and SVF (β = 0.004, p = 0.002) scores. After stratification by sex, these findings were significant only in men, where SF was associated with increased TDS (β = 0.003, p = 0.01), PVF (β = 0.004, p = 0.03), and SVF (β = 0.004, p = 0.009) scores. In middle-aged subjects, SF was also associated with increased SVF scores (β = 0.005, p = 0.011). Lastly, in men, SF levels were negatively associated with R2*, a surrogate marker of brain iron content, in both the left frontal inferior opercular area (r = -0.41, p = 0.005) and the right frontal inferior opercular area (r = -0.44, p = 0.002). Conclusions: SF is significantly and positively associated with cognition. In older people with low SF levels, iron supplementation may be a promising therapy to improve cognition.